Insmed Incorporated (NASDAQ:INSM) Director Sells $231,725.00 in Stock

Insmed Incorporated (NASDAQ:INSM - Get Free Report) Director David W. J. Mcgirr sold 3,250 shares of the company's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $71.30, for a total value of $231,725.00. Following the sale, the director now owns 100,723 shares of the company's stock, valued at approximately $7,181,549.90. This trade represents a 3.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Insmed Stock Up 1.2%

Shares of NASDAQ:INSM traded up $0.88 on Friday, reaching $73.62. The company had a trading volume of 1,558,246 shares, compared to its average volume of 2,072,473. Insmed Incorporated has a 52-week low of $55.74 and a 52-week high of $84.91. The firm's 50 day simple moving average is $69.28 and its 200-day simple moving average is $73.03. The firm has a market capitalization of $13.41 billion, a PE ratio of -13.17 and a beta of 0.80. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The company had revenue of $92.82 million during the quarter, compared to analysts' expectations of $91.63 million. During the same quarter in the prior year, the business posted ($1.06) earnings per share. The company's revenue was up 22.9% compared to the same quarter last year. As a group, analysts expect that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in INSM. Blue Trust Inc. grew its stake in Insmed by 25.7% during the 4th quarter. Blue Trust Inc. now owns 2,462 shares of the biopharmaceutical company's stock worth $180,000 after buying an additional 503 shares during the last quarter. Spire Wealth Management purchased a new position in Insmed during the 4th quarter worth $47,000. Jennison Associates LLC grew its stake in Insmed by 0.6% during the 4th quarter. Jennison Associates LLC now owns 773,813 shares of the biopharmaceutical company's stock worth $53,424,000 after buying an additional 4,560 shares during the last quarter. abrdn plc grew its stake in Insmed by 159.5% during the 4th quarter. abrdn plc now owns 289,653 shares of the biopharmaceutical company's stock worth $19,998,000 after buying an additional 178,041 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in Insmed by 3.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,401 shares of the biopharmaceutical company's stock worth $446,000 after buying an additional 186 shares during the last quarter.

Wall Street Analyst Weigh In

A number of analysts recently commented on INSM shares. Guggenheim reiterated a "buy" rating and set a $101.00 price objective on shares of Insmed in a research report on Tuesday, February 25th. Royal Bank of Canada reiterated an "outperform" rating and set a $100.00 target price on shares of Insmed in a research report on Wednesday, March 19th. UBS Group cut their target price on Insmed from $110.00 to $109.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Wells Fargo & Company raised their price target on Insmed from $85.00 to $107.00 and gave the company an "overweight" rating in a report on Wednesday, February 19th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Insmed in a research note on Wednesday, February 19th. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $96.73.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.